] was a 40-week, double-blind, randomized, placebo-controlled, phase 3 trial to assess efficacy, safety, and tolerability of GIP/GLP-1 receptor co-agonist tirzepatide monotherapy vs. placebo in adults with T2D inadequately controlled by diet and exercise alone. Here, GLP1R is linked to type 2 diabetes mellitus.